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Abstract
Peripheral blood eosinophilia and vascular occlusions are rare occurrences in patients with pleural
mesothelioma whereas eosinophilia may associate with thrombosis. We describe a patient with
mesothelioma who developed peripheral blood eosinophilia followed by deep vein thrombosis
despite being on low molecular weight heparin prophylaxis. We discuss the genesis of peripheral
blood eosinophilia and thrombosis in pleural mesothelioma.
Introduction
The latest nationwide census from the occupational
United Kingdom physicians identified pleural mesotheli-
oma (PM) in 92% of lung cancers patients [1] whereas PM
represented only 8% of histology proven lung cancers
accrued from an area without heavy industrial exposure to
asbestos [2]. Peripheral blood eosinophilia (PBE) has
been detected in 0.5% to 1.7% of patients with malig-
nancy [3]: it may occur in cancer of the lung, pancreas,
uterus, liver, breast, kidney and thyroid [3,4], in liposarco-
mas [5] in lymphomas and T-cell-leukemias [6,7] but it is
quite rare in PM [8-11]. PBE is associated with metastatic
spread, predicts a poor prognosis [12,13], may disappear
with treatment of the malignancy and reappear with
tumour relapse [6,14]. We describe a patient who devel-
oped PBE almost coincidentally with PM followed by
deep vein thrombosis despite low molecular weight
heparin prophylaxis and in the absence of inherited
thrombophilia.
Case report
A 75-year old gentleman was admitted to the Oncology/
Haematology Ward in early September 2007 for severe
shortness of breath. He had been fully investigated for a
pleural effusion one month earlier in a neighbouring hos-
pital. At that time drained pleural fluid revealed reactive
lymphocytes with neither neutrophils nor eosinophils.
However peripheral blood esosinophils were raised at 1.6
× 109/L, C-reactive protein (CRP) at 33 mg/dl and fibrin-
ogen at 568 mg/dl. Cultures for bacteria and stains for
acid-fast bacilli were negative. Several stool examinations
and serologic tests were negative for parasites as well as an
autoimmune screen (antinuclear antibodies, antineu-
trophil-cytoplasmic antibodies, anti myeloperoxidase
antibodies). A right pleural biopsy done in mid August
2007 revealed sheets of pleura infiltrated by malignant
epithelioid cells that on immune staining expressed CK7
(cytokeratin) with focal expression of CK5/6 whereas
staining for carcino-embriogenic antigen, BerEP4, thyroid
transcription factor-1 mesothelin, Wilms' tumour -1,
CK20 or prostate specific antigen was negative, confirm-
ing a diagnosis of epithelioid mesothelioma. A drain was
inserted through the right chest wall and opiates started
(morphine sulphate 30 modified release bd, oxycodone).
During the current admission the drain was re-sited and
fluid examination revealed only reactive lymphocytes and
few neutrophils. His peripheral blood eosinophils had
risen to 21 × 109/L, CRP was up at 88 mg/dl and fibrino-
gen at 880 mg/dl. The patient was started on a prophylac-
tic dose of tinzaparin (3500 IU/day). On the fourth day
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after admission the patient developed a swollen calf, his
D-dimer was greater than 1000 mg/dl (cut-off normal
>280 mg/dl) and an ultrasound scan confirmed a fresh
popliteal vein thrombosis. Tinzaparin was increased to
therapeutic levels for five days until warfarin brought the
international normalised ratio within therapeutic range. A
thrombophilia screen (including factor V Leiden, pro-
thrombin 20210, protein C, protein S, antithrombin,
lupus anticoagulant and anticardiolipin antibodies)
arranged before commencing warfarin came back normal.
Neither the FIP1L1-PDGFRA fusion transcript (deletion
4q12) nor other cytogenetic abnormalities were found on
a cellular sample of peripheral blood. After 5 days later his
general conditions deteriorated, he became progressively
confused with increasing hypoxia and passed away for res-
piratory failure. Post mortem revealed a mesothelioma
that had diffusely surrounded and invaded the left lung
and pericardium without directly affecting vascular struc-
tures. No asbestos bodies were found and no pulmonary
embolism was detected.
Discussion
PBE is rare finding in mesothelioma: a large survey found
one case out of 4710 patients with pleural involvement
[8] whereas two more patients with pleural involvement
[9,10] and one with peritoneal involvement [11] have
been described as case reports. In this setting PBE should
be considered reactive as the tumour itself produces fac-
tors that promote eosinophil generation such as inter-
leukin 3, interleukin 5 and granulocyte-monocyte colony
stimulating factor [15]. The negative cytogenetic testing
favours a reactive PBE in our patient.
Thrombosis development in PM is also rare: according to
one series venous occlusions occurred in 6.5% (1/15) of
cases [16], whereas an autopsy study on 111 patients with
lung cancer identified 14 cases of PM of which 14% had
evidence of clots in the venous circulation [17]; isolated
reports documented occlusions of the superior vena cava
[18,19], of the left jugular and subclavian veins [20] and
of the portal vein [21]. Arterial occlusions affected cere-
bral circulation in two cases [22,23] and mesenteric ves-
sels in one case (associated with nephrotic
syndrome)[24].
The pathogenesis of thrombosis in PM is partly due to
tumour tissue compressing veins [18,20] that at times
may progress to direct vessel infiltration [19] and partly
due to a hypercoagulable state characterised by elevated
levels of plasma fibrinogen [25] and increased fibrin turn-
over leading to disseminated intravascular coagulation
[26].
Primary eosinophilic syndrome is strongly associated
with thrombosis that may be recurrent despite adequate
heparin and warfarin anticoagulation [27]. Eosinophils
store and express tissue factor and once activated may ini-
tiate coagulation [28]. In addition eosinophils interfere
with the activity of natural anticoagulants: eosinophilic
cationic protein (ECP) binding to thrombomodulin pre-
vents thrombin dependent activation of anticoagulant
protein C [29] and binding to heparan sulphate (or
heparin) prevents the conformational change required for
the anti-thrombin neutralisation of thrombin [30].
Indeed an excess of ECP was able to override heparin
binding to antithrombin [31] and may well explain the
few instances where apparently therapeutic or prophylac-
tic doses of heparin failed to prevent thrombosis [27,32].
This was the situation of our patient who developed deep
vein thrombosis being already on prophylactic low
molecular weight heparin.
In conclusion we have reported an unprecedented patient
with pleural mesothelioma in whom reactive PBE contrib-
uted to the development of deep vein thrombosis more
than the tumour itself on the background of an inflamma-
tory and eventually hypercoagulable state. Though diffi-
cult for mesothelioma, tumour treatment may relieve the
reactive PBE [6,14]. Clinicians should be aware of the
added thrombotic risk of hypereosinophilia in cancer
patients [33] and consider prophylactic or therapeutic
anticoagulation according to clinical judgement and lab-
oratory guidance, possibly with anti factor Xa monitoring
in the case of low molecular weight heparin.
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